The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors
Carucci, Margherita, Clamp, Andrew, Zhou, Cong, Hurt, Chris, Glasspool, Rosalind, Monaghan, Phillip J, Thirkettle, Sally, Wheatley, Michael, Mahmood, Madia, Narasimham, Monica, Cox, Tracy, Morrison, Hilary, Campbell, Susan, Nelson, Annmarie, Holland-Hart, Daniella, Hopewell-Kelly, Noreen, Thomas, Abin, Porter, Catharine, Slusarczyk, Magdalena, Irving, Alys, Dive, Caroline, Adams, Richard, Jayson, Gordon C
Published in BMC cancer (24.10.2024)
Published in BMC cancer (24.10.2024)
Get full text
Journal Article
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
Jones, Robert H, Casbard, Angela, Carucci, Margherita, Cox, Catrin, Butler, Rachel, Alchami, Fouad, Madden, Tracie-Ann, Bale, Catherine, Bezecny, Pavel, Joffe, Johnathan, Moon, Sarah, Twelves, Chris, Venkitaraman, Ramachandran, Waters, Simon, Foxley, Andrew, Howell, Sacha J
Published in The lancet oncology (01.03.2020)
Published in The lancet oncology (01.03.2020)
Get full text
Journal Article
BI06 Short sharp shock or slow burn: clinician perspectives on treatment of actinic keratoses with 5-fluorouracil 5% cream monotherapy vs. 5-fluorouracil/calcipotriol ointment combination therapy
Junejo, Muhammad Hyder, Carucci, Margherita, Hurt, Chris, Adams, Richard, Matin, Rubeta, Proby, Charlotte, Harwood, Catherine
Published in British journal of dermatology (1951) (26.06.2023)
Published in British journal of dermatology (1951) (26.06.2023)
Get full text
Journal Article
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial
Howell, Sacha J, Casbard, Angela, Carucci, Margherita, Ingarfield, Kate, Butler, Rachel, Morgan, Sian, Meissner, Magdalena, Bale, Catherine, Bezecny, Pavel, Moon, Sarah, Twelves, Chris, Venkitaraman, Ramachandran, Waters, Simon, de Bruin, Elza C, Schiavon, Gaia, Foxley, Andrew, Jones, Robert H
Published in The lancet oncology (01.07.2022)
Published in The lancet oncology (01.07.2022)
Get full text
Journal Article
CoRInTH: A phase Ib/II trial of checkpoint inhibitor, pembrolizumab (PD-1 antibody [Ab]) plus standard intensity modulated chemoradiotherapy (IMCRT) in HPV-induced stage III squamous cell carcinoma (SCC) of the anus
Hall, Marcia, Adams, Richard, Guren, Marianne Grønlie, Carucci, Margherita, Nixon, Lisette, Porter, Catharine, Bhuva, Neel, Glynne-Jones, Robert, Harrison, Mark
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Fulvestrant plus capivasertib for metastatic breast cancer – Authors' reply
Jones, Robert H, Casbard, Angela, Carucci, Margherita, Foxley, Andrew, Howell, Sacha J
Published in The lancet oncology (01.05.2020)
Published in The lancet oncology (01.05.2020)
Get full text
Journal Article
Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor–positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with enhanced biomarker analysis
Jones, Robert Hugh, Casbard, Angela Claire, Carucci, Margherita, Ingarfield-Herbert, Kate, Butler, Rachel, Morgan, Sian, Meissner, Magdalena, Bale, Catherine Jane, Bezecny, Pavel, Moon, Sarah, Twelves, Chris, Venkitaraman, Ramachandran, Waters, Simon, De Bruin, Elza, Schiavon, Gaia, Foxley, Andrew, Howell, Sacha Jon
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Tracking endocrine resistance in estrogen-receptor positive breast cancer in ctDNA
Meissner, Magdalena, Butler, Rachel, Casbard, Angela Claire, Carucci, Margherita, Madden, Tracie-Ann, Howell, Sacha Jon, Jones, Robert Hugh
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article
Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial
Jones, Robert Hugh, Carucci, Margherita, Casbard, Angela Claire, Butler, Rachel, Alchami, Fouad, Bale, Catherine Jane, Bezecny, Pavel, Joffe, Johnathan, Moon, Sarah, Twelves, Chris, Venkitaraman, Ramachandran, Waters, Simon, Howell, Sacha Jon
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article
Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial
Beresford, Mark, Casbard, Angela, Hudson, Zoe, Carucci, Margherita, Ingarfield, Kate, Gee, Julia, Smith, Joanna, Kitson, Terri, Alchami, Fouad, Madden, Tracie-Ann, Hayward, Larrie, Hwang, David, Spensley, Saiqa, Waters, Simon, Wheatley, Duncan, Jones, Robert H.
Published in BJC reports (14.09.2023)
Published in BJC reports (14.09.2023)
Get full text
Journal Article
The Dangers of Female Mobility in Roman Imperial Times
Margherita Carucci
Published in The Impact of Mobility and Migration in the Roman Empire (29.11.2016)
Get full text
Published in The Impact of Mobility and Migration in the Roman Empire (29.11.2016)
Book Chapter